Search Results - "ROBLIN, Xavier"

Inflammatory bowel disease: towards a personalized medicine by Flamant, Mathurin, Roblin, Xavier

“…The management of inflammatory bowel disease (IBD) has been transformed over the last two decades by the arrival of tumor necrosis factor (TNF) antagonist…”
Get full text

Letter: immunogenicity of anti‐TNF in elderly IBD patients by Paul, Stephane, Roblin, Xavier

“…Linked ContentThis article is linked to Singh et al and Singh and Jairath papers. To view these articles, visit https://doi.org/10.1111/apt.15214 and…”
Get full text

NOD2 deficiency increases retrograde transport of secretory IgA complexes in Crohn’s disease by Rochereau, Nicolas, Roblin, Xavier, Michaud, Eva, Gayet, Rémi, Chanut, Blandine, Jospin, Fabienne, Corthésy, Blaise, Paul, Stéphane

“…Intestinal microfold cells are the primary pathway for translocation of secretory IgA (SIgA)-pathogen complexes to gut-associated lymphoid tissue. Uptake of…”
Get full text

Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review by Martelli, Laura, Olivera, Pablo, Roblin, Xavier, Attar, Alain, Peyrin-Biroulet, Laurent

“…Background Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The…”
Get full text

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial by Vermeire, Séverine, Prof, Schreiber, Stefan, Prof, Petryka, Robert, MD, Kuehbacher, Tanja, Prof, Hebuterne, Xavier, Prof, Roblin, Xavier, MD, Klopocka, Maria, PhD, Goldis, Adrian, MD, Wisniewska-Jarosinska, Maria, MD, Baranovsky, Andrey, Prof, Sike, Robert, MD, Stoyanova, Kremena, MD, Tasset, Chantal, PhD, Van der Aa, Annegret, PhD, Harrison, Pille, DPhil

“…Summary Background Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined…”
Get full text

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions by Ward, Mark G., Sparrow, Miles P., Roblin, Xavier

“…The introduction of vedolizumab, a lymphocyte adhesion inhibitor, has expanded the relatively limited therapeutic armamentarium available for Crohn’s disease…”
Get full text

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases by Roblin, Xavier, Rinaudo, M, Del Tedesco, E, Phelip, J M, Genin, C, Peyrin-Biroulet, L, Paul, S

“…Several decision algorithms based on the measurement of infliximab (IFX) trough levels and antibodies to IFX have been proposed. Whether such algorithms can be…”
Get full text

Use of imaging modalities for decision-making in inflammatory bowel disease by Nancey, Stéphane, Fumery, Mathurin, Faure, Mathias, Boschetti, Gilles, Gay, Claire, Milot, Laurent, Roblin, Xavier

“…Cross-sectional magnetic resonance enterography (MRE) and intestinal ultrasonography (IUS) provide valuable and noninvasive information to accurately assess…”
Get full text

Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cells by Rochereau, Nicolas, Drocourt, Daniel, Perouzel, Eric, Pavot, Vincent, Redelinghuys, Pierre, Brown, Gordon D, Tiraby, Gerard, Roblin, Xavier, Verrier, Bernard, Genin, Christian, Corthésy, Blaise, Paul, Stéphane

“…Intestinal microfold (M) cells possess a high transcytosis capacity and are able to transport a broad range of materials including particulate antigens,…”
Get full text

S1201 Impact of Baseline Albumin Levels on Ozanimod Efficacy: A Post Hoc Analysis of the Phase 3 True North Study by Cross, Raymond K., Barnes, Edward L., Cheifetz, Adam S., Ben-Horin, Shomron, Roblin, Xavier, Yarur, Andres, Liu, Zhaohui, Mehra, Dimpy, Harris, Sarah, Osterman, Mark T., Lawlor, Garrett, Jain, Anjali, Dulai, Parambir S.

Get full text

S733 Impact of Inflammatory Burden on Efficacy of Upadacitinib Maintenance Therapy in Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study by Feagan, Brian G., Colombel, Jean-Frederic, Torres, Joana, Fujii, Toshimitsu, Zhou, Wen, Yao, Xuan, Sanchez-Gonzalez, Yuri, Ilo, Dapo, Roblin, Xavier

Get full text

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study by Rayer, Cassandra, Nachury, Maria, Bourreille, Arnaud, Roblin, Xavier, Peyrin-Biroulet, Laurent, Viennot, Stephanie, Flamant, Mathurin, Laharie, David, Caron, Bénédicte, Dewitte, Marie, Siproudhis, Laurent, Fumery, Mathurin, Bouguen, Guillaume

“…No study has performed a face-to-face comparison of biologics after the failure of the first anti-TNF agent in patients with Crohn's disease (CD). The aim of…”
Get full text

New methods to unveil host-microbe interaction mechanisms along the microbiota-gut-brain-axis by Moradian, Habibullah, Gabriel, Tristan, Barrau, Mathilde, Roblin, Xavier, Paul, Stéphane

“…Links between the gut microbiota and human health have been supported throughout numerous studies, such as the development of neurological disease disorders…”
Get full text

Cytomegalovirus Load in Inflamed Intestinal Tissue Is Predictive of Resistance to Immunosuppressive Therapy in Ulcerative Colitis by ROBLIN, Xavier, PILLET, Sylvie, OUSSALAH, Abderrahim, BERTHELOT, Philippe, TEDESCO, Emilie Del, PHELIP, Jean-Marc, CHAMBONNIERE, Marie-Laure, GARRAUD, Olivier, PEYRIN-BIROULET, Laurent, POZZETTO, Bruno

“…Previous studies have suggested an association between cytomegalovirus (CMV) infection and steroid-refractory inflammatory bowel disease. In this study, the…”
Get full text

Health care-associated hepatitis C virus infection by Pozzetto, Bruno, Memmi, Meriam, Garraud, Olivier, Roblin, Xavier, Berthelot, Philippe

“…Hepatitis C virus(HCV)is a blood-borne pathogen that has a worldwide distribution and infects millions of people.Care-associated HCV infections represented a…”
Get full text

S914 Safety of Filgotinib in Crohn’s Disease Compared with Ulcerative Colitis: Data from the Phase 3 DIVERSITY1 and Phase 2b/3 SELECTION Studies by Schreiber, Stefan, Vermeire, Séverine, Rubin, David T., Danese, Silvio, Mehta, Rajiv, Roblin, Xavier, Kwon, Paul, van Hoek, Paul, Masior, Tomasz, Barron, Rahul, Le Brun, Franck-Olivier, Watanabe, Mamoru

Get full text

S904 Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy for Crohn’s Disease: Results From the Phase 3 Randomized, Double-Blind, Placebo-Controlled DIVERSITY1 Study by Vermeire, Séverine, Rubin, David T., Watanabe, Mamoru, Schreiber, Stefan, Mehta, Rajiv, Roblin, Xavier, Genovese, Mark C., Masior, Tomasz, Barron, Rahul, Le Brun, Franck-Olivier, Danese, Silvio

Get full text

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies by Berger, Anne Emmanuelle, Gleizes, Aude, Waeckel, Louis, Roblin, Xavier, Krzysiek, Roman, Hacein-Bey-Abina, Salima, Soriano, Alessandra, Paul, Stephane

“…Background. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decisions using specialized algorithms, especially in…”
Get full text

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis by Billioud, Vincent, Ford, Alexander C., Tedesco, Emilie Del, Colombel, Jean-Frédéric, Roblin, Xavier, Peyrin-Biroulet, Laurent

“…About one-third of inflammatory bowel disease (IBD) patients still require surgery. A growing number of them receive anti-tumor necrosis factor (TNF) therapy…”
Get full text

No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification by Paul, Stephane, Williet, Nicolas, Nancey, Stéphane, Veyrard, Pauline, Boschetti, Gilles, Phelip, Jean-Marc, Flourie, Bernard, Roblin, Xavier

“…Introduction The pharmacokinetic equivalence of dose intensification with adalimumab (ADA) 80 mg every other week (EOW) compared to weekly 40 mg has only been…”
Get full text